Vertex Pharmaceuticals Inc (VRTX) 115.93 $VRTX
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.10 (-0.15), BIIB: 320.75 (-2.72), VRTX: 115.93 (-1.36), AFFX: 9.43 (-0.02)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 5.11% Rise
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 5.11% Gain
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 05, 11:07AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 17.23% as of today's recent price of $112.39.
VRTX: 115.93 (-1.36)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 91.06 (-3.49), VRTX: 115.93 (-1.36), BMRN: 83.91 (-0.12), GILD: 106.45 (-0.49), ALXN: 193.81 (+0.67)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.93 (-1.36), GERN: 2.33 (-0.07), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Business Wire - Wed Nov 05, 6:02AM CST
---Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation-
VRTX: 115.93 (-1.36)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.20 (-0.81), VRTX: 115.93 (-1.36), GILD: 106.45 (-0.49), MRK: 59.34 (+0.08), ABBV: 61.50 (-1.21)
Vertex to Present at the Credit Suisse Healthcare Conference on November 11
Business Wire - Thu Oct 30, 3:02PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET.
VRTX: 115.93 (-1.36)
Why You Shouldn't Worry About Gilead Sciences, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Oct 30, 7:10AM CDT
Source: Gilead Sciences It shouldn't be too shocking to learn that sales of Gilead Sciences ' mega blockbuster Sovaldi sagged in the third quarter. After all, prescriptions written for Sovaldi declined steadily throughout the quarter ahead of...
JNJ: 108.20 (-0.81), VRTX: 115.93 (-1.36), GILD: 106.45 (-0.49)
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 12:00PM CDT
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), JNJ: 108.20 (-0.81), VRTX: 115.93 (-1.36)
Uptrend Call Working As Vertex Pharmaceuticals Stock Rises 15.3% (VRTX)
Comtex SmarTrend(R) - Wed Oct 29, 9:45AM CDT
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 1 month, Vertex Pharmaceuticals has returned 15.30% as of today's recent price of $110.54.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals (VRTX) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Oct 29, 9:44AM CDT
The following Vertex Pharmaceuticals (VRTX) conference call took place on October 28, 2014, 05:00 PM ET. This is a transcript of that earnings call:
VRTX: 115.93 (-1.36)
Arrival of Former FDA Senior Officials Accelerates Greenleaf Expansion
Business Wire - Wed Oct 29, 7:00AM CDT
Greenleaf Health LLC (Greenleaf) today announced the arrival of two former senior officials from the U.S. Food and Drug Administration (FDA), John Taylor and Joseph Griffin, and a former Government Affairs official from Vertex Pharmaceuticals, Brian T. Corrigan. The three join a staff of experts from FDA, Capitol Hill, and top global pharmaceutical and biotechnology organizations. "With the addition of John, Joe, and Brian to our existing team, Greenleaf is broadening the scope and depth of services it can provide clients to help them navigate the complex FDA regulatory environment," said Patrick Ronan, Greenleaf President and former FDA Chief of Staff.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals Incorporated Plays the Earnings Waiting Game
Brian Orelli, The Motley Fool - Motley Fool - Tue Oct 28, 6:48PM CDT
Sales of Vertex Pharmaceuticals ' cystic fibrosis drug, Kalydeco, increased 25% year over year in the third quarter, but that's nothing compared with the sales potential for its cystic fibrosis drug franchise. It just has to get the drugs...
VRTX: 115.93 (-1.36)
Vertex tops Street 3Q forecasts
AP - Tue Oct 28, 5:58PM CDT
BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Tuesday reported a loss of $170.1 million in its third quarter.
VRTX: 115.93 (-1.36)
Vertex Reports Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:02PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014. Vertex reported total third quarter 2014 GAAP revenues of $179 million, including revenues of $127 million from KALYDECO(R) (ivacaftor). The GAAP net loss for the third quarter of 2014 was $(170) million, or $(0.72) per share, which includes net charges of $84 million. The non-GAAP net loss for the third quarter of 2014 was $(86) million, or $(0.37) per share. The company also today provided updated financial guidance for total 2014 non-GAAP revenues, 2014 KALYDECO revenues and non-GAAP operating expenses. As of September 30, 2014, Vertex had $1.48 billion in cash, cash equivalents and marketable securities.
VRTX: 115.93 (-1.36)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 1.53% Yesterday
Comtex SmarTrend(R) - Mon Oct 27, 5:18PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $107.86 to a high of $111.78. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $111.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.53%
Comtex SmarTrend(R) - Mon Oct 27, 5:17PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $107.86 to a high of $111.78. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $111.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:40PM CDT
Aegerion has an Earnings ESP of -25.00% and carries a Zacks Rank #3.
ACT: 245.91 (-4.47), VRTX: 115.93 (-1.36), TEVA: 57.70 (-1.02), AEGR: 21.58 (-0.40)
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.10 (-0.15), BIIB: 320.75 (-2.72), VRTX: 115.93 (-1.36), AFFX: 9.43 (-0.02)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 5.11% Rise
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 5.11% Gain
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 05, 11:07AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 17.23% as of today's recent price of $112.39.
VRTX: 115.93 (-1.36)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 91.06 (-3.49), VRTX: 115.93 (-1.36), BMRN: 83.91 (-0.12), GILD: 106.45 (-0.49), ALXN: 193.81 (+0.67)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.93 (-1.36), GERN: 2.33 (-0.07), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Business Wire - Wed Nov 05, 6:02AM CST
---Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation-
VRTX: 115.93 (-1.36)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.20 (-0.81), VRTX: 115.93 (-1.36), GILD: 106.45 (-0.49), MRK: 59.34 (+0.08), ABBV: 61.50 (-1.21)
Vertex to Present at the Credit Suisse Healthcare Conference on November 11
Business Wire - Thu Oct 30, 3:02PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET.
VRTX: 115.93 (-1.36)
Why You Shouldn't Worry About Gilead Sciences, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Oct 30, 7:10AM CDT
Source: Gilead Sciences It shouldn't be too shocking to learn that sales of Gilead Sciences ' mega blockbuster Sovaldi sagged in the third quarter. After all, prescriptions written for Sovaldi declined steadily throughout the quarter ahead of...
JNJ: 108.20 (-0.81), VRTX: 115.93 (-1.36), GILD: 106.45 (-0.49)
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 12:00PM CDT
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), JNJ: 108.20 (-0.81), VRTX: 115.93 (-1.36)
Uptrend Call Working As Vertex Pharmaceuticals Stock Rises 15.3% (VRTX)
Comtex SmarTrend(R) - Wed Oct 29, 9:45AM CDT
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 1 month, Vertex Pharmaceuticals has returned 15.30% as of today's recent price of $110.54.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals (VRTX) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Oct 29, 9:44AM CDT
The following Vertex Pharmaceuticals (VRTX) conference call took place on October 28, 2014, 05:00 PM ET. This is a transcript of that earnings call:
VRTX: 115.93 (-1.36)
Arrival of Former FDA Senior Officials Accelerates Greenleaf Expansion
Business Wire - Wed Oct 29, 7:00AM CDT
Greenleaf Health LLC (Greenleaf) today announced the arrival of two former senior officials from the U.S. Food and Drug Administration (FDA), John Taylor and Joseph Griffin, and a former Government Affairs official from Vertex Pharmaceuticals, Brian T. Corrigan. The three join a staff of experts from FDA, Capitol Hill, and top global pharmaceutical and biotechnology organizations. "With the addition of John, Joe, and Brian to our existing team, Greenleaf is broadening the scope and depth of services it can provide clients to help them navigate the complex FDA regulatory environment," said Patrick Ronan, Greenleaf President and former FDA Chief of Staff.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals Incorporated Plays the Earnings Waiting Game
Brian Orelli, The Motley Fool - Motley Fool - Tue Oct 28, 6:48PM CDT
Sales of Vertex Pharmaceuticals ' cystic fibrosis drug, Kalydeco, increased 25% year over year in the third quarter, but that's nothing compared with the sales potential for its cystic fibrosis drug franchise. It just has to get the drugs...
VRTX: 115.93 (-1.36)
Vertex tops Street 3Q forecasts
AP - Tue Oct 28, 5:58PM CDT
BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Tuesday reported a loss of $170.1 million in its third quarter.
VRTX: 115.93 (-1.36)
Vertex Reports Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:02PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014. Vertex reported total third quarter 2014 GAAP revenues of $179 million, including revenues of $127 million from KALYDECO(R) (ivacaftor). The GAAP net loss for the third quarter of 2014 was $(170) million, or $(0.72) per share, which includes net charges of $84 million. The non-GAAP net loss for the third quarter of 2014 was $(86) million, or $(0.37) per share. The company also today provided updated financial guidance for total 2014 non-GAAP revenues, 2014 KALYDECO revenues and non-GAAP operating expenses. As of September 30, 2014, Vertex had $1.48 billion in cash, cash equivalents and marketable securities.
VRTX: 115.93 (-1.36)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 1.53% Yesterday
Comtex SmarTrend(R) - Mon Oct 27, 5:18PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $107.86 to a high of $111.78. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $111.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
Vertex Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.53%
Comtex SmarTrend(R) - Mon Oct 27, 5:17PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $107.86 to a high of $111.78. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $111.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.93 (-1.36)
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:40PM CDT
Aegerion has an Earnings ESP of -25.00% and carries a Zacks Rank #3.
ACT: 245.91 (-4.47), VRTX: 115.93 (-1.36), TEVA: 57.70 (-1.02), AEGR: 21.58 (-0.40)
